Novocure Announces Presentations on Tumor Treating Fields Therapy, Including New Clinical Data and Real-World Evidence, at 2023 Society for Neuro-Oncology Annual Meeting
11 November 2023 - 12:00AM
Business Wire
Novocure (NASDAQ: NVCR) today announced that research on Tumor
Treating Fields (TTFields) therapy, including new data from the
phase 2 2-THE-TOP trial and real-world evidence from patients
diagnosed with glioblastoma (GBM) and other central nervous system
tumors (CNS), will be presented at the 2023 Society for
Neuro-Oncology (SNO) Annual Meeting from Nov. 16 to Nov. 19 in
Vancouver, Canada.
Novocure’s presence at the SNO Annual Meeting will include
medical booths, sponsored symposia and scientific presentations
spanning preclinical, clinical and real-world outcomes research
underscoring the safety and efficacy of TTFields therapy, as well
as patient and healthcare provider satisfaction with the
therapy.
“The SNO Annual Meeting is the largest annual conference focused
on neuro-oncology and an ideal forum for sharing new data on the
use of immunotherapy and TTFields therapy in the treatment of GBM
as well as our largest real-world study to date and additional
insights about the safety and efficacy of TTFields therapy,” said
Frank Leonard, President of Novocure’s U.S. CNS Cancers Franchise.
“We are eager to engage with the neuro-oncology community as we
strive to extend survival in some of the most aggressive forms of
cancer.”
Highlights include:
- an oral presentation of data from the 2-THE-TOP trial,
suggesting TTFields therapy had an enhanced effect with
pembrolizumab in patients with newly diagnosed GBM. 2-THE-TOP is an
investigator-sponsored phase 2 clinical trial of TTFields therapy
plus pembrolizumab plus maintenance temozolomide.
- an oral presentation of the final results of Novocure’s largest
non-interventional real-world evidence study to date, the TTFields
in Germany in Routine Clinical Care (TIGER) study in patients with
newly diagnosed glioblastoma (GBM). A striking 82% of the 710
patients surveyed opted to use TTFields therapy and demonstrated
sustained health-related quality of life, except for more itchy
skin, consistent with results from the randomized, phase 3 EF-14
clinical study.
Novocure is also sponsoring an Independent Supported Session,
titled Tumor Treating Fields vs. GBM —The Evidence and Experience,
on Friday, Nov. 17, from 12:45-1:45 p.m. PST in Room 208-209,
Vancouver Convention Centre.
A CME/Industry Sponsored Symposium, PeerView Live at SNO 2023,
Shattering the Barriers to Glioblastoma Care: Revolutionary
Advances With Innovative Technologies and Modern Systemic
Approaches (in collaboration with the American Brain Tumor
Association), will be held Thursday, Nov. 15 at 5:30-6:30 p.m. PST
in Room 205-207, Vancouver Convention Centre.
The 2023 SNO Annual Meeting will also mark the debut of
Novocure’s new Optune Gio™ brand. Optune®, Novocure’s FDA-approved
treatment for newly diagnosed and recurrent GBM, will be renamed
Optune Gio™ on Nov. 15.
Presentations include:
- Final efficacy and correlative analyses of 2-THE-TOP: A
pilot study of TTFields (Optune) plus pembrolizumab plus
maintenance temozolomide in patients with newly diagnosed
glioblastoma (ndGBM). Presenter: David D. Tran. 8:06 p.m. PST
on Friday, Nov. 17.
- Treatment decision and quality of life of patients with
newly diagnosed glioblastoma (ndGBM) receiving Tumor Treating
Fields (TTFields) therapy in routine clinical care: First results
of the TIGER study. Presenter: Martin Glas. 8:35 a.m. PST on
Saturday, Nov. 18
- Demographics, prescribing patterns, and satisfaction of
healthcare professionals who prescribe Tumor Treating Fields
(TTFields) therapy to patients with glioblastoma. Presenter:
Elena Palmesino. 7:30 p.m. PST on Friday, Nov. 17.
- Tumor Treating Fields (TTFields) therapy in glioblastoma
(GBM): relationship between patient experience, global region, and
age. Presenter: Eleni T. Batzianouli. 7:30 p.m. PST on Friday,
Nov. 17.
- Long-term global post-marketing surveillance data from
pediatric, adult and elderly patients with central nervous system
malignancies treated with Tumor Treating Fields (TTFields)
therapy. Presenter: Maciej M. Mrugala. 7:30 p.m. PST on Friday,
Nov. 17.
- Real world experience with TTFields with emphasis on therapy
compliance. Presenter: Claudius Jelgersma. 7:30 p.m. PST on
Friday, Nov. 17.
- Prolonged follow-up of an oligodendroglioma patient with
history of Tumor Treating Fields (TTF) as post chemo-radiation
maintenance therapy. Presenter: Xiao-Tang Kong. 7:30 p.m. PST
on Friday, Nov. 17
- Distant progression to the posterior fossa in supratentorial
glioblastoma: A report of three cases during Tumor Treating Fields
therapy. Presenter: Juri Kiyowaka. 7:30 p.m. PST on Friday,
Nov. 17
- Advanced MRI Biomarkers Predict Early Response to Tumor
Treating Fields in Glioblastoma. Presenter: Kathleen Schmainda.
7:30 p.m. PST on Friday, Nov. 17
- Investigating safety and efficacy of TTFields prior and
concomitant to radiotherapy in newly diagnosed glioblastoma - first
results of the PriCoTTF phase I/II trial. Presenter: Sied
Kebir. 7:30 p.m. PST on Friday, Nov. 17
- The pivotal METIS (EF-25) study of Tumor Treating Fields
(TTFields) therapy for brain metastases from non-small cell lung
cancer (NSCLC) following radiosurgery. Presenter: Minesh P.
Mehta. 7:30 p.m. PST on Friday, Nov. 17
- The pivotal TRIDENT study of Tumor Treating Fields
(TTFields) therapy with chemoradiation, followed by maintenance
TTFields therapy/temozolomide (TMZ), in newly diagnosed
glioblastoma (ndGBM). Presenter: Wenyin Shi. 7:30 p.m. PST on
Friday, Nov. 17
- Adopting Tumor Treating Fields (TTFields) therapy for
glioblastoma and other solid cancers: challenges and
opportunities. Presenter: Leonardo Lustgarten. 7:30 p.m. PST on
Friday, Nov. 17
- Tumor Treating Fields: Real-World Survival and Quality of
Life Outcomes on the XCELSIOR Platform. Presenter: Joshua
Palmer. 7:30 p.m. PST on Friday, Nov. 17
- Development of Tumor Treating Fields (TTFields) arrays for
treatment of head tumors in mice models. Presenter: Moshe
Giladi. 7:30 p.m. PST on Friday, Nov. 17
- Molecular characterization of glioma tissue after TTFields
treatment. Presenter: Christian Mawrin. 7:30 p.m. PST on
Friday, Nov. 17
- Dielectric properties of intracranial tumors – role of
myelin content. Presenter: Martin A. Proescholdt. 7:30 p.m. PST
on Friday, Nov. 17
About Tumor Treating Fields Therapy
Tumor Treating Fields (TTFields) are electric fields that exert
physical forces to kill cancer cells via a variety of mechanisms.
TTFields do not significantly affect healthy cells because they
have different properties (including division rate, morphology, and
electrical properties) than cancer cells. The multiple, distinct
mechanisms of TTFields therapy work together to selectively target
and kill cancer cells. Due to its multimechanistic actions,
TTFields therapy can be added to cancer treatment modalities in
approved indications and demonstrates enhanced effects across solid
tumor types when used with chemotherapy, radiotherapy, immune
checkpoint inhibition, or targeted therapies in preclinical models.
TTFields therapy provides clinical versatility that has the
potential to help address treatment challenges across a range of
solid tumors. To learn more about Tumor Treating Fields therapy and
its multifaceted effect on cancer cells, visit
tumortreatingfields.com.
About Optune
Optune is a noninvasive, antimitotic cancer treatment for
glioblastoma (GBM). Optune delivers Tumor Treating Fields
(TTFields) therapy to the region of the tumor.
TTFields therapy uses electric fields to disrupt cell division.
TTFields therapy does not stimulate or heat tissue and targets
dividing cancer cells of a specific size. TTFields therapy takes
advantage of the special characteristics and geometrical shape of
dividing cells, which make them susceptible to the effects of the
alternating electric fields. TTFields therapy causes minimal damage
to healthy cells. Mild to moderate skin irritation is the most
common side effect reported. TTFields therapy is approved in
certain countries for the treatment of adults with glioblastoma,
malignant pleural mesothelioma and pleural mesothelioma, some of
the most difficult cancer types to treat. The therapy shows promise
in multiple solid tumor types – including some of the most
aggressive forms of cancer.
About Novocure
Novocure is a global oncology company working to extend survival
in some of the most aggressive forms of cancer through the
development and commercialization of its innovative therapy, Tumor
Treating Fields. Novocure’s commercialized products are approved in
certain countries for the treatment of adult patients with
glioblastoma, malignant pleural mesothelioma and pleural
mesothelioma. Novocure has ongoing or completed clinical trials
investigating Tumor Treating Fields in brain metastases, gastric
cancer, glioblastoma, liver cancer, non-small cell lung cancer,
pancreatic cancer and ovarian cancer.
Headquartered in Root, Switzerland and with a growing global
footprint, Novocure has regional operating centers in Portsmouth,
New Hampshire and Tokyo, as well as a research center in Haifa,
Israel. For additional information about the company, please visit
Novocure.com and follow @Novocure on LinkedIn and Twitter.
Forward-Looking Statements
In addition to historical facts or statements of current
condition, this press release may contain forward-looking
statements. Forward-looking statements provide Novocure’s current
expectations or forecasts of future events. These may include
statements regarding anticipated scientific progress on its
research programs, clinical trial progress, development of
potential products, interpretation of clinical results, prospects
for regulatory approval, manufacturing development and
capabilities, market prospects for its products, coverage,
collections from third-party payers and other statements regarding
matters that are not historical facts. You may identify some of
these forward-looking statements by the use of words in the
statements such as “anticipate,” “estimate,” “expect,” “project,”
“intend,” “plan,” “believe” or other words and terms of similar
meaning. Novocure’s performance and financial results could differ
materially from those reflected in these forward-looking statements
due to general financial, economic, environmental, regulatory and
political conditions as well as issues arising from the COVID-19
pandemic and other more specific risks and uncertainties facing
Novocure such as those set forth in its Annual Report on Form 10-K
filed on February 23, 2023, and subsequent filings with the U.S.
Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements. Furthermore, Novocure does
not intend to update publicly any forward-looking statement, except
as required by law. Any forward-looking statements herein speak
only as of the date hereof. The Private Securities Litigation
Reform Act of 1995 permits this discussion.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231110051782/en/
Investors: Ingrid Goldberg investorinfo@novocure.com
610-723-7427
Media: Leigh Labrie media@novocure.com 610-723-7428
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2024 to May 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From May 2023 to May 2024